ICBII Update on the Road to the Cure - April 2022 · Parkinson's Resource Organization

ICBII Update on the Road to the Cure - April 2022

Category: Road to the Cure

Blood-Brain Barrier Continues to be the Main Thorn in CNS Drug Development

Editorial remarks by Jo Rosen: In 1998 I was told by Robert W. Rand, MtD, a nationally and internationally known neurosurgeon and Professor of Neurosurgery at UCLA, and in 2003 I was told by Professor of Neuroscience, and Professor of Neurosurgery and  neurology at the University of Kentucky, Greater Lexington, Dr. Greg Gerhardt, that chances are we would never find a cure for Parkinson’s or other neurological disorders unless and until we could permeate the Blood-Brain-Barrier.

Now read this…

What is the Blood-Brain Barrier (BBB)? To define the BBB, it is necessary to understand that although our brain is a part of the same body, there are two distinct zones in the body: the peripheral system (below the neck) and the central nervous system, CNS, (above the neck). The brain belongs to the central nervous system. Our brain, in essence, is the engine that controls the function of our entire body. So, it is the most important organ in the body and that is why Nature did everything possible to protect this organ.  

Nature gave us the skull to protect our brain from external injuries. To protect the brain further, the same Nature built a very tight network of capillary tubes, known as blood vessels, in the brain to supply blood to our brain. The brain is powered by about 600 kilometers of tightly knit blood vessels that bring it nutrients from the peripheral system to the brain and remove waste products. This tight network of blood vessels in the brain is what known as the tight protective barrier, the blood-brain barrier (BBB), that guards our brain from toxic substances that may be present in the peripheral system. This barrier does not allow, for our own well-being, entrance of chemicals, toxic substances, pharmaceuticals, viruses, bacteria, pesticides, and tumor cells present in the peripheral system into the central nervous system. In other words, the BBB acts as the security guard as to what can or cannot enter the brain. 

Unfortunately, the same tight security control of the BBB has become an unsurmountable problem for centuries to deliver therapeutic drugs to the brain when we get sick with Alzheimer’s, Parkinson’s, or any other brain disease. This BBB currently inhibits the entry of nearly 98% of all drugs and nearly 100% of all macromolecular drugs that can potentially change the course of the disease. Consequently, in the 21st century, we still do not have curative therapies for most of the central nervous system diseases, though the global scientific and medical community have been trying for decades to successfully deliver drugs to the brain. 

ICBI International has permeated/breached the BBB. Next month, we will share what ICB International, Inc. has accomplished to overcome the problem of the blood-brain barrier impermeability and developing potentially curative therapies for diseases like Parkinson’s.

WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBI directly through their website ICBII.com or by phone 858-455-9880, or contact Jo Rosen at PRO for a personal introduction to the scientists.

IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease.

JUST IMAGINE.

Share This Article:

Google+

Contact Us

Address
Parkinson's Resource Organization
74785 Highway 111
Suite 208
Indian Wells, CA 92210

Local Phone
(760) 773-5628

Toll-Free Phone
(877) 775-4111

General Information
info@parkinsonsresource.org

 

Like! Subscribe! Share!

Did you know that you can communicate with us through Facebook, Twitter, LinkedIn, YouTube, and now Instagram?

PRIVACY POLICY TEXT

 

Updated: August 16, 2017